secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004423
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apellis reports preliminary 2022 EMPAVELI US net sales of ~$65M; NDA and MAA submitted
--------------------------------------------------------------------------------

- Preliminary unaudited 2022 US net product revenue for EMPAVELI ~$65 million.
- Submitted New Drug Application to US FDA and Marketing Authorization Application to EMA for pegcetacoplan.
- Appointed Dr. Caroline Baumal as Chief Medical Officer effective Q1 2023.
- Completed enrollment in Phase 2 ALS study; progressed late-stage pipeline with partner Sobi.
- Deployed ~100 field-based employees mid-2022 for US commercial launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312523004423/0001193125-23-004423-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312523004423/d436376d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004423

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer